Scholarlink

<p>There is no definite effective treatment modality for multiple warts. Intralesional Candida antigen can yield high response rates, but it can also be associated with various constitutional manifestations, including fever, bone and muscle aches, vomiting, and abdominal pain. While the bivalent HPV vaccine can give variable clinical improvements, it may have higher recurrence rates in responding cases. To assess the clinical outcomes regarding recurrence, response, and side effects after combining intralesional Candida antigen with the bivalent HPV vaccine over their use as monotherapy.&#xa0;A randomized clinical trial involving 150 patients with multiple warts divided into three groups (A, B, and C) received intralesional Candida antigen, bivalent HPV vaccine, or both at 2-week intervals for five sessions.&#xa0;Complete remission was obtained in 68% of the patients in the Candida antigen group, 28% in the bivalent HPV vaccine group, and 74% in the combined group. Local tissue reaction and flu-like symptoms were significantly higher in the Candida antigen group than in the other two groups. The recurrence rate in the responding group was 0% in the combined group.&#xa0;The combined immunotherapeutic treatment may have more advantages regarding response, side effects, or recurrence rates than mono-therapeutic agents.</p><p>Clinicaltrials.gov listing: NCT05291845.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multiple verruca: can combined intralesional immunotherapy improve the clinical outcomes?

  • 期刊论文

  • 发表日期：

    2025年12月20日

查看全文
  • Ahmad Nofal,
  • Reham Essam,
  • Maha W. Khater,
  • Emad A. Moustafa,
  • Rana Ehab

摘要

There is no definite effective treatment modality for multiple warts. Intralesional Candida antigen can yield high response rates, but it can also be associated with various constitutional manifestations, including fever, bone and muscle aches, vomiting, and abdominal pain. While the bivalent HPV vaccine can give variable clinical improvements, it may have higher recurrence rates in responding cases. To assess the clinical outcomes regarding recurrence, response, and side effects after combining intralesional Candida antigen with the bivalent HPV vaccine over their use as monotherapy. A randomized clinical trial involving 150 patients with multiple warts divided into three groups (A, B, and C) received intralesional Candida antigen, bivalent HPV vaccine, or both at 2-week intervals for five sessions. Complete remission was obtained in 68% of the patients in the Candida antigen group, 28% in the bivalent HPV vaccine group, and 74% in the combined group. Local tissue reaction and flu-like symptoms were significantly higher in the Candida antigen group than in the other two groups. The recurrence rate in the responding group was 0% in the combined group. The combined immunotherapeutic treatment may have more advantages regarding response, side effects, or recurrence rates than mono-therapeutic agents.

Clinicaltrials.gov listing: NCT05291845.